Shares of Humana Inc. (NYSE:HUM – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $493.38.
HUM has been the topic of a number of analyst reports. Truist Financial raised their price objective on shares of Humana from $460.00 to $490.00 in a research note on Thursday, April 7th. Morgan Stanley raised their price target on shares of Humana from $410.00 to $436.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 9th. Loop Capital began coverage on Humana in a report on Thursday, June 16th. They issued a “buy” rating and a $510.00 price target for the company. UBS Group raised Humana from a “neutral” rating to a “buy” rating and upped their target price for the stock from $486.00 to $520.00 in a research note on Wednesday, April 13th. Finally, Wells Fargo & Company lifted their price target on shares of Humana from $512.00 to $514.00 and gave the company an “overweight” rating in a research note on Wednesday, May 25th.
NYSE HUM opened at $448.05 on Friday. Humana has a 1 year low of $351.20 and a 1 year high of $472.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.53. The company has a market capitalization of $56.68 billion, a PE ratio of 19.01, a P/E/G ratio of 1.24 and a beta of 0.86. The company has a fifty day moving average of $442.33 and a 200 day moving average of $433.88.
The company also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Thursday, June 30th will be given a dividend of $0.7875 per share. The ex-dividend date is Wednesday, June 29th. This represents a $3.15 annualized dividend and a dividend yield of 0.70%. Humana’s payout ratio is 13.36%.
In related news, CAO William Kevin Fleming sold 3,210 shares of the stock in a transaction that occurred on Thursday, April 28th. The stock was sold at an average price of $449.68, for a total value of $1,443,472.80. Following the completion of the transaction, the chief accounting officer now directly owns 884 shares in the company, valued at $397,517.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Timothy S. Huval sold 3,477 shares of Humana stock in a transaction on Thursday, April 28th. The shares were sold at an average price of $443.14, for a total value of $1,540,797.78. Following the completion of the sale, the insider now owns 5,768 shares in the company, valued at approximately $2,556,031.52. The disclosure for this sale can be found here. Insiders sold 10,644 shares of company stock valued at $4,702,360 in the last three months. 0.39% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in HUM. Tcwp LLC acquired a new position in shares of Humana in the 1st quarter worth approximately $25,000. Spire Wealth Management acquired a new position in Humana during the fourth quarter worth $30,000. BerganKDV Wealth Management LLC boosted its position in shares of Humana by 885.7% during the fourth quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock worth $32,000 after buying an additional 62 shares during the period. Riverview Trust Co acquired a new stake in shares of Humana in the first quarter valued at $32,000. Finally, Selective Wealth Management Inc. acquired a new position in Humana during the 4th quarter worth about $35,000. Institutional investors and hedge funds own 94.93% of the company’s stock.
Humana Company Profile (Get Rating)
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.